You are here: Industry Insights > AZD7442

News List

Matrix Collaborates with AstraZeneca on Trial for COVID-19 Long-Acting Antibody Combination americanpharmaceuticalreview
February 09, 2021
Matrix Medical Network® announced a collaboration with AstraZeneca to accelerate a clinical trial in the US for AZD7442, AstraZeneca's long-acting monoclonal antibody (LAAB) combination for the potential prevention of COVID-19.
Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial contractpharma
January 27, 2021
Care Access to provide decentralized, mobile research site operations for AstraZeneca’s AZD7442 Phase III trial in the U.S.
AstraZeneca starts COVID-19 prevention trial for immunocompromised patients europeanpharmaceuticalreview
November 24, 2020
The trial will evaluate if the long-acting monoclonal antibody cocktail, AZD7442, can prevent COVID-19 in patients who cannot be vaccinated.
AstraZeneca begins trials on antibody cocktail to prevent COVID-19 expresspharma
November 23, 2020
The prophylactic treatment may prove useful in people whose immune systems are weaker or compromised, and who don’t respond to vaccination.
Lonza to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination contractpharma
November 02, 2020
cGMP manufacturing of the two long-acting antibodies to begin in H1 2021 at Lonza's Portsmouth, NH (USA) site.
AstraZeneca, U.S. Govt. Enter $486M COVID-19 Antibody Agreement contractpharma
October 22, 2020
Funding will be used for two Phase III trials and related development and manufacturing activities for the supply of AZD7442 doses in the U.S.
US enters agreement for experimental prophylactic COVID-19 antibody cocktail europeanpharmaceuticalreview
October 15, 2020
The US government will develop and manufacture AstraZeneca’s investigational monoclonal antibody cocktail, AZD7442, a potential prophylactic treatment for COVID-19.
COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials worldpharmanews
October 14, 2020
AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are due to begin in the this weeks.
AstraZeneca secures $486m from US for Covid-19 antibody pharmaceutical-technology
October 14, 2020
AstraZeneca has received an investment of approximately $486m from the US Government to develop and supply its long-acting antibody (LAAB) cocktail, AZD7442, for Covid-19 treatment.
AstraZeneca doses first patients in COVID-19 therapy trial europeanpharmaceuticalreview
August 27, 2020
The Phase I trial will assess the safety and pharmacokinetics of the AZD7442 monoclonal antibody combination in 48 healthy participants.

Previous page 1 2 3 Next page